Tectonic Therapeutic, Inc. (TECX)
(Delayed Data from NSDQ)
$19.32 USD
+0.33 (1.74%)
Updated Nov 7, 2025 04:00 PM ET
After-Market: $19.33 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
NA Value NA Growth NA Momentum NA VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TECX 19.32 +0.33(1.74%)
Will TECX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for TECX based on the 1-3 month trading system that more than doubles the S&P 500.

Other News for TECX
20 Day Moving Average Support appears for TECX after 1.74% move
Tectonic Therapeutic Reports Q3 2025 Financial Results
TECX Crossed Above 20 Day Moving Average on November 6
Piper Sandler Sticks to Its Buy Rating for Tectonic Therapeutic (TECX)
Promising Outlook for Tectonic Therapeutic: Buy Rating Affirmed Amid Strong Financials and Progress in TX45 Trial